Hepatitis B Foundation President Dr. Chari Cohen is quoted in a powerful new story about hepatitis B in The New Yorker. You can read it here.

Dr. Yasmin Ibrahim appointed to national Patient Engagement Collaborative

The panel advises the U.S. Food and Drug Administration as to engaging patients in medical product regulation.

Doylestown, Pa. – Jan. 11, 2022 – The U.S. Food and Drug Administration and the Clinical Trials Transformation Initiative (CTTI) has announced eight newly selected representatives for the Patient Engagement Collaborative, including Yasmin Ibrahim, MD, PhD, MBA, of the Hepatitis B Foundation.

According to the CTTI, “The group of 16 patients, caregivers, and patient group representatives will meet with the FDA several times a year to discuss topics such as communication, transparency, and the best ways for patients to engage the FDA about medical product regulation.”

The eight new representatives, who are expected to serve two-year terms, are: Kim Hindery, Yasmin Ibrahim of the Hepatitis B Foundation, Seth Morgan, Cara O’Neill, Ceciel Rooker, Christina Sisti, Trina Stelly and Lauren Youngborg.

Yasmin Ibrahim, MD, PhD, MBA, of the Hepatitis B Foundation

Yasmin Ibrahim, MD, PhD, MBA, of the Hepatitis B Foundation

Dr. Ibrahim is the Hepatitis B Foundation’s senior program manager for public health.

“Yasmin provides strong leadership for the Foundation’s efforts to engage patients in our work and is passionate about incorporating the voices of people living with hepatitis B in everything we do,” Chari A. Cohen, DrPH, MPH, president of the Hepatitis B Foundation said. “It’s a true testament to her efforts that she is being recognized by the FDA and the Clinical Trials Transformation Initiative as a consistent advocate and partner of people living with hepatitis B.”

Read more about the Patient Engagement Collaborative here.